dismiss

Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment
Advertisement

 

advertisement

 

Molecular Imaging Homepage

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Dennis Durmis MITA names chair of board of directors

Researchers find new PET tracer that better detects melanoma than 18F-FDG 18F-P3BZA could become the new gold standard

FDA clears United Imaging's total-body PET scanner Creating 3D images of entire human body in 15-30 seconds

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Rob Beanlands ASNC names president for 2019

Former South African nuclear executives to appeal suspensions in court Involves monthslong shutdown of NTP Radioisotopes medical isotope plant

NIC has awarded RadioMedix $2 million
for the clinical development of
AlphaMedix

RadioMedix scores $2 million contract for Targeted Alpha-emitter therapy

John R. Fischer , Staff Reporter
The National Cancer Institute, part of the National Institutes of Health, has granted RadioMedix a two-year, $2 million Phase II SBIR contract for the clinical development of its Targeted Alpha-emitter Therapy (TAT) for neuroendocrine tumors.

The award follows and is a continuation of the success of its Phase I SBIR contract around the use of 212Pb-octreotate analog (AlphaMedix) for patients with advanced neuroendocrine tumors (NETS) who have limited treatment options available to them.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510



"Current approaches to cancer treatment are largely ineffective once the tumor has metastasized. Neuroendocrine tumors are rare, accounting for only 0.5% of all malignancies and their symptoms are usually vague and nonspecific," Izabela Tworowska, CSO of RadioMedix and the principal investigator of the SBIR Phase II contract, told HCB News. "Surgery is the principal therapy for localized disease however its success in advanced disease is limited. The combination chemotherapy used for management of NETs is associated with high toxicity and limited efficacy."

A heterogeneous group of rare neoplasms, neuroendocrine tumors stem from neuroendocrine cells and appear primarily in the gastrointestinal tract and pancreas, expressing somatostatin receptors. They can also occur in the thymus, lung and uncommon sites such as the cervix, heart and prostate.

AlphaMedix is a radiolabeled SSTR-targeting therapeutic investigation drug designed to treat NETs patients. Its composition consists of SSTR-targeting peptide complex radiolabeled with 212Pb, enabling it to act as a vivo generator of alpha-emitting particles. Its half-life, high energy, short path length of decay and irreversible damage to the double stranded DNA make it a well suited-source for SSTR therapy applications.

The Phase I clinical study was designed based on the results of the pre-clinical toxicity and efficacy studies performed with the scope of the NCI NIH Phase I Contract. The award builds on the progress made in this non-randomized, open-label, dose escalation study, with the NIH NCI Phase II Contract focused on determining the safety and pharmacokinetics of Pb212-octreotate (AlphaMedix) and selecting the effective doses for therapy of patients with somatostatin receptor positive neuroendocrine tumors.

"The recent FDA approval of 177Lu-DOTATATE (Lutathera, Advanced Accelerated Applications, currently Novartis) highlights the growth of the radiotherapeutic market. Despite this great success, there is a significant potential for improvement in safety, efficacy and lengthening progression free survival of patients by using targeted alpha emitter-therapy," said Tworowska. "Our hypothesis is that alpha emitters such as 212Pb with higher linear energy transfer (LET) and shorter path-length in tissue can deliver lethal dose to the tumor cells, causing permanent double strand DNA damage and less damage to the normal tissue. These characteristics should translate into the higher efficacy and safety of the treatment."

RadioMedix recently scored another award in the form of a fast-track designation by the FDA for 64-Cu-Dotatate, an investigational diagnostic radiopharmaceutical that it’s developing and commercializing alongside Curium.

The project is funded with federal funds from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services.

Clinical studies around the use of AlphaMedix are currently underway at the Excel Diagnostics and Nuclear Oncology Center in Houston.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2019 DOTmed.com, Inc.
版权所有